CureVac N.V. announced financial results for the first quarter of 2025, reporting revenues of €0.9 million. The company's cash and cash equivalents stood at €438.3 million as of March 31, 2025, with the expected cash runway reaffirmed into 2028.
The glioblastoma study (CVGBM) completed enrollment of Part B of its Phase 1 trial in Q1 2025, with a go/no-go decision for advancing to Phase 2 planned for the second half of 2025. The U.S. FDA cleared the IND for CVHNLC, its off-the-shelf lung cancer candidate, with the clinical study expected to begin in the second half of 2025.
The company's core mRNA patents were upheld by the European Patent Office, confirming the validity of two key patents in amended form. An infringement hearing against BioNTech/Pfizer is set for July 1, 2025, before the Regional Court Düsseldorf.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.